Advanced, AI-based technology imaging solution recognized for accelerating clinical development
PHILADELPHIA – February 21, 2019 – ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced its advanced technology imaging solution has been named a finalist in the 2019 Informa Clinical and Research Excellence (CARE) Award, Best Technological Development in Clinical Trials – Sponsor-focused category.
“The 2019 CARE Awards showcase the significant accomplishments and innovations that are occurring across our industry – from rare disease drug development and patient-centric trials, to product and technological development,” said Karen M. Currie, MPH, Executive Director, Editorial, Citeline, Informa. “We are pleased to recognize ERT as a finalist for their unwavering commitment to delivering solutions that produce higher quality data so that clinical trial sponsors can accelerate the development of new medical treatments.”
ERT’s advanced technology imaging solution is purpose-built for managing the complete lifecycle of imaging in clinical trials, enabling sponsors to improve imaging data consistency, objectivity and transparency and to run more efficient studies. It enables the analysis, management, reporting and submission of high-quality imaging data that meets regulators’ increasing requests for imaging endpoints in clinical development. Having processed over 3 million images to date, ERT’s proven imaging solution continues to be rapidly adopted by pharmaceutical researchers – from small biotechs to large, global organizations – based on the significant advantages it offers over other imaging approaches.
“We’re honored to be recognized by the CARE judging panel as a finalist for this year’s award,” said Tim Kulbago, Vice President of Imaging, ERT. “It’s rewarding to see the industry acknowledge how our innovative software and AI-based solution overcomes the inefficiencies of traditional imaging processes to deliver the highest quality data and accelerate clinical development.”
For more information on ERT’s imaging solution for clinical research, visit ert.com/imaging.
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials. ERT’s solutions measure treatment efficacy, ensure patient safety, enable effective data integration and analytics, and deliver real-world insights so that its customers can move ahead with confidence.
Since 2013, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date. By identifying trial risks before they become problems, ERT enables its customers to bring clinical treatments to patients quickly ─ and with confidence.